SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-24-049213
Filing Date
2024-04-26
Accepted
2024-04-26 16:30:10
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A ikt-proxy-2024_defa14a.htm DEFA14A 9923
2 GRAPHIC img217228029_0.jpg GRAPHIC 3031633
3 GRAPHIC img217228029_1.jpg GRAPHIC 2275018
  Complete submission text file 0000950170-24-049213.txt   7302628
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 263407249 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39676 | Film No.: 24884342
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)